Lyerly HK - Search Results

1

CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S. Wang X, et al. Among authors: lyerly hk. J Natl Cancer Inst. 2010 Oct 6;102(19):1496-512. doi: 10.1093/jnci/djq343. Epub 2010 Sep 17. J Natl Cancer Inst. 2010. PMID: 20852124 Free PMC article.

2

Optimizing dendritic cell function by genetic modification.

Lyerly HK, Clay T, Morse MA. Lyerly HK, et al. J Natl Cancer Inst. 2000 Aug 2;92(15):1198-9. doi: 10.1093/jnci/92.15.1198. J Natl Cancer Inst. 2000. PMID: 10922398 No abstract available.

3

Monitoring cellular immune responses to cancer immunotherapy.

Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK. Morse MA, et al. Among authors: lyerly hk. Curr Opin Mol Ther. 2001 Feb;3(1):45-52. Curr Opin Mol Ther. 2001. PMID: 11249731 Review.

4

Surrogate markers of effective anti-tumor immunity.

Lyerly HK, Morse MA, Clay TM. Lyerly HK, et al. Ann Surg Oncol. 2001 Apr;8(3):190-1. doi: 10.1007/s10434-001-0190-6. Ann Surg Oncol. 2001. PMID: 11314932 No abstract available.

5

Assays for monitoring cellular immune responses to active immunotherapy of cancer.

Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Clay TM, et al. Among authors: lyerly hk. Clin Cancer Res. 2001 May;7(5):1127-35. Clin Cancer Res. 2001. PMID: 11350875 Review.

6

Quantitating therapeutically relevant T-cell responses to cancer vaccines.

Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA. Hobeika AC, et al. Among authors: lyerly hk. Crit Rev Immunol. 2001;21(1-3):287-97. Crit Rev Immunol. 2001. PMID: 11642610 Review.

7

Surrogate markers of response to cancer immunotherapy.

Morse MA, Clay TM, Hobeika AC, Mosca PJ, Lyerly HK. Morse MA, et al. Among authors: lyerly hk. Expert Opin Biol Ther. 2001 Mar;1(2):153-8. doi: 10.1517/14712598.1.2.153. Expert Opin Biol Ther. 2001. PMID: 11727526

8

Dendritic cell maturation in active immunotherapy strategies.

Morse MA, Mosca PJ, Clay TM, Lyerly HK. Morse MA, et al. Among authors: lyerly hk. Expert Opin Biol Ther. 2002 Jan;2(1):35-43. doi: 10.1517/14712598.2.1.35. Expert Opin Biol Ther. 2002. PMID: 11772338 Review.

9

Current status of adoptive immunotherapy of malignancies.

Morse MA, Clay TM, Lyerly HK. Morse MA, et al. Among authors: lyerly hk. Expert Opin Biol Ther. 2002 Mar;2(3):237-47. doi: 10.1517/14712598.2.3.237. Expert Opin Biol Ther. 2002. PMID: 11890864 Review.

10

Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes.

Clay TM, Morse M, Lyerly HK. Clay TM, et al. Among authors: lyerly hk. Expert Opin Biol Ther. 2002 Apr;2(4):353-60. doi: 10.1517/14712598.2.4.353. Expert Opin Biol Ther. 2002. PMID: 11955274 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

306 results

Search Page

Filters